Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Novel concept in chronic lymphoid leukemia treatment

Novel concept in chronic lymphoid leukemia treatment

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Novel leukemia therapy shows promise for high-risk patients

Novel leukemia therapy shows promise for high-risk patients

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

New technique sees into tissue at greater depth, resolution

New technique sees into tissue at greater depth, resolution

Leukaemia drug may reverse multiple sclerosis brain damage

Leukaemia drug may reverse multiple sclerosis brain damage

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Peregrine Pharmaceuticals reports on phase II trial of Bavituximab plus Docetaxel in advanced breast cancer

Biothera initiates second phase of metastatic colorectal cancer trial

Biothera initiates second phase of metastatic colorectal cancer trial

Outlook for Crohn's disease improves due to new therapies

Outlook for Crohn's disease improves due to new therapies

Lilly to acquire ImClone Systems for $6.5 billion

Lilly to acquire ImClone Systems for $6.5 billion

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

Eli Lilly starts second global phase III trial of investigational Alzheimer's disease compound

New results help predict treatment response in colorectal cancer

New results help predict treatment response in colorectal cancer

Merck Serono and Ablynx to jointly develop nanobodies

Merck Serono and Ablynx to jointly develop nanobodies

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Panacea Pharmaceuticals issued U.S. patent for anti-HAAH antibodies

Discovery of new genes for inflammatory bowel disease in children

Discovery of new genes for inflammatory bowel disease in children

Genmab announces four studies of ofatumumab in chronic lymphocytic leukemia

Genmab announces four studies of ofatumumab in chronic lymphocytic leukemia

Amgen announces positive results for Denosumab postmenopausal osteoporosis trial

Amgen announces positive results for Denosumab postmenopausal osteoporosis trial

New center for protein therapeutics formed by UB pharmaceutical scientists

New center for protein therapeutics formed by UB pharmaceutical scientists

Nanotechnology, biomolecules, and light unite to "cook" cancer cells

Nanotechnology, biomolecules, and light unite to "cook" cancer cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.